Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880670 | 1.00 | GSR (0.33) | GSRALDH1A1ENPEPF2CPB2 | |
| SCHEMBL16278935 | 1.00 | GSR (0.33) | GSRALDH1A1ENPEPF2CPB2 | |
| SCHEMBL16285772 | 0.95 | GSR (0.39) | GSRALDH1A1ENPEPF2CPB2 | |
| SCHEMBL16279005 | 0.91 | GABRR1 (0.32) | BHMT | |
| SCHEMBL16279002 | 0.91 | GABRR1 (0.32) | BHMT | |
| SCHEMBL16285804 | 0.84 | GSR (0.34) | GSRALDH1A1ENPEPCPB2 | |
| SCHEMBL16285773 | 0.84 | KDM7A (0.32) | BHMT | |
| SCHEMBL22005470 | 0.84 | RNPEP (0.34) | F2CPB2 | |
| SCHEMBL16278956 | 0.82 | ALDH1A1 (0.33) | GSRALDH1A1 | |
| SCHEMBL16278958 | 0.82 | ALDH1A1 (0.33) | GSRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190350908-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE BY PROMOTING PREMATURE TERMINATION CODON READ-THROUGH | MOONSHOT PHARMA LLC | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350908-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE BY PROMOTING PREMATURE TERMINATION CODON READ-THROUGH | UPF1, RNGTT, NSUN2 | GSR 4569/4885ALDH1A1 4854/4885ENPEP 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.